Antibody-mediated rejection after kidney transplantation in children; therapy challenges and future potential...

Area of Science:

• Nephrology
• Transplantation immunology

Background:

• Antibody-mediated rejection (AMR) significantly impacts renal transplant outcomes.
• Current treatments for AMR lack FDA approval in the US and face challenges due to limited research, especially in pediatric cases.
• Ambiguous definitions and lack of clear guidelines complicate AMR management in pediatric nephrology.

Purpose of the Study:

• To review current and emerging treatments for antibody-mediated rejection (AMR) in renal transplantation.
• To provide guidance for clinicians managing AMR in pediatric renal transplant recipients.
• To focus on the latest Transplantation Society (TTS) recommendations for AMR classification and therapy.

Main Methods:

• Literature review of current and emerging AMR treatments.
• Analysis of the Transplantation Society (TTS) guidelines for AMR.
• Focus on pediatric considerations and evidence.

Main Results:

• No FDA-approved treatments currently exist for AMR in the United States.
• Treatment strategies for AMR are often controversial and lack a gold standard.
• Pediatric AMR treatment is particularly challenging due to limited studies and poorly documented side effects of some therapies.

Conclusions:

• There is a critical need for standardized and effective treatments for AMR, particularly in pediatric renal transplantation.
• Adherence to updated TTS guidelines can help standardize AMR management.
• Further research is essential to develop and validate novel therapies for AMR with a focus on safety and efficacy in children.